Research & Development

Mycovia, Jiangsu Hengrui to develop and commercialize antifungal therapy VT-1161

Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine announced an exclusive agreement to develop and commercialize Mycovia’s investigational drug, VT-1161 (otesaconazole), in China, including mainland China, Hong Kong, Macau, and Taiwan, for the treatment or prevention of a range of fungal conditions, including recurrent vulvovaginal candidiasis (RVVC), onychomycosis and invasive fungal infections.

Pfizer to buy Array BioPharma for £9.06bn

Pfizer has signed an agreement to acquire commercial stage biopharmaceutical firm, Array BioPharma, for an enterprise value of around $11.4bn (£9.06bn).

IBM, KPMG, Merck and Walmart to assess use of blockchain to protect pharmaceutical product integrity

IBM, KPMG, Merck and Walmart announced that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a program in support of the US Drug Supply Chain Security Act (DSCSA) that addresses requirements to identify, track and trace prescription medicines and vaccines distributed within the US.

Vernalis, PhoreMost announce drug discovery collaboration for novel oncology target

Ligand Pharmaceuticals and PhoreMost have announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.

Dassault Systèmes to buy Medidata Solutions for £4.5bn

Dassault Systèmes has signed an agreement to acquire US-based Medidata Solutions for an enterprise value of $5.8bn (£4.5bn).

Boehringer Ingelheim, University of Dundee extend anti-cancer alliance

Following the success of their ongoing alliance, Boehringer Ingelheim and the University of Dundee extend their collaboration to develop new medicines that target and destroy key cancer causing proteins.

Aptar acquires Nanopharm and Gateway Analytical to accelerate customer drug development

AptarGroup has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical, for a combined enterprise value of approximately $50m (£39.3m).

Merck to buy biopharmaceutical firm Tilos Therapeutics in £608m deal

Merck has signed an agreement to acquire biopharmaceutical firm Tilos Therapeutics in a deal valued at around $773m (£608m).

nference enters into R&D data science partnership with Janssen

nference, a leader in knowledge synthesis software solutions for the life sciences industry, today announced a multi-year alliance with Janssen Research & Development, LLC that will leverage the nference artificial intelligence (AI) platform to create a unified data science-powered connective fabric across the Janssen R&D organization.